Last updated on April 20, 2014 at 17:20 EDT

Robotic Prostatectomy, Laser BPH Sales from Intuitive Surgical, AMS, Lumenis Fuel European Urological Device Market to Over EUR1.6 Billion

April 24, 2012

TURP Device Sales in Spain, France and the U.K. Drive Growth in the BPH
Treatment Market

VANCOUVER, April 24, 2012 /PRNewswire/ – According to a new report by iData
Research (www.idataresearch.net), the leading global authority in medical device market research, the
European urological device market, was valued at over EUR1 Billion in
2011. Growth will be fueled by increased sales of robotic prostatectomy
for the treatment of prostate cancer, particularly in Germany and
Italy. The BPH treatment market is also expected to grow rapidly,
driven by sales of Laser BPH and TURP devices, particularly in Spain,
France and the UK.

“In 2011, interventional BPH was the fastest-growing urological
procedure performed in Europe,” says Dr. Kamran Zamanian, CEO of iData.
“Growth is being fueled by improved diagnosis and early treatment due
to increased awareness and a decline in social stigma associated with
many urological disorders.”

The report states that AMS and Lumenis are battling for control of the
rapidly-growing laser BPH market, while Olympus and Karl Storz are
vying for control of the TURP device market. Increased use of bipolar
electrodes is driving up the value of the TURP market, as the devices
are significantly more expensive than monopolar electrodes and
accounted for more than 87% of devices used.

Additionally, the robotic prostatectomy is expected to be the
fastest-growing segment within the overall urological device market.
Intuitive Surgical is currently the sole competitor in Europe with its
da Vinci® systems.

“The robotic prostatectomy market in Europe is being fueled by adoption
by surgeons as an effective technique for the treatment of prostate
cancer,” says Dr. Zamanian. “The technique is considered to have
increased precision and safety over other options such as open or
laparoscopic prostatectomy.”

For more information, register free on iData’s website at:

iData’s 3-report series on the: “Markets for Urological Devices 2012″
includes the U.S., Europe (15 countries) and Asia-Pacific (3 countries)
and covers the treatment of benign prostatic hyperplasia (BPH),
prostate cancer, urinary incontinence and urological stones.

About iData Research

iData Research (www.idataresearch.net/idata/discoveridata.php) is an international market research and consulting group focused on
providing market intelligence for medical device, dental and
pharmaceutical companies. iData covers research in: urology, endoscopy,
women’s health and more.

SOURCE iData Research Inc.

Source: PR Newswire